ultraIPV™ is produced using a proprietary inactivation technology developed by BMI and its collaborators. Briefly, the viruses are complexed with a manganese-decapeptide-phosphate (MDP) mixture and then exposed to UV light. A very quick, easy and reproducible process. The MDP system has been adapted from radiation-resistant bacteria such as Deinococcus radiodurans.
ultraIPV™ is produced using the attenuated Sabin strains which reduces safety and security concerns. The inactivation process uses ultraviolet light which appears to be less damaging to the immunogenic surface features of the virus. The process is rapid (less than a minute compared with 2-4 weeks for formalin-inactivation) and requires less downstream processing that IPV. ultraIPV™ stimulates high titers of virus-neutralizing antibodies in animal models.
The global polio vaccine market is estimated at about 1.5Bn USD and is expected to grow to over 4Bn USD over the next six years. Due to its advantages over existing products, ultraIPV™ has the potential to disrupt and take over a large portion of the growing polio vaccine market within a short time period.
The MDP-UV inactivation method is a platform technology. BMI and its collaborators are applying the technology to the development of vaccines against additional important human pathogens, such as MRSA and Acinetobacter baumannii, two hard-to-treat bacteria that are resistant to multiple antibiotics.